Back to top
more

ResMed (RMD)

(Real Time Quote from BATS)

$211.66 USD

211.66
486,139

-4.50 (-2.08%)

Updated May 8, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down

Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.

3 GARP Stocks to Scoop up for Maximum Returns

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.

Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View

Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.

Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall

Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.

Integra's (IART) Q1 Earnings Match Estimates, Margins Down

Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.

Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View

Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.

Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Sheraz Mian headshot

Top Research Reports for Apple, Linde & Comcast

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Comcast Corporation (CMCSA).

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up

Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.

Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up

Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.

DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its first-quarter performance.

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline

Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.

Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise

Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.

Ritujay Ghosh headshot

4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts

Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.

Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised

BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.

Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts

Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.

Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics

Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.

Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up

Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.

CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up

CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.